



SAIK





Slovenská asociácia
intervenčnej kardiológie

Scaffold: Zombie alebo návrat z mŕtvych?


Anton Farkaš

Kardiocentrum AGEL Košice

„Revolúcia v koronárnej intervencii“



MeRes100 scaffold



MeRes1 Trial




Table 2. Cumulative clinical outcomes at 3-year follow-up.

| Events | In-hospital n=108 | 6-month n=108 | 1-year n=107 | 2-year n=107 | 3-year n=107 |
|---|----------------------|------------------|-----------------|-----------------|-----------------|
| Cardiac death, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Non-cardiac death, n (%) | 0 (0) | 1 (0.93)* | 1 (0.93) | 1 (0.93) | 1 (0.93) |
| Myocardial infarction, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ID-TLR ¹ , n (%) | 0 (0) | 0 (0) | 1 (0.93) | 2 (1.87) | 2 (1.87) |
| Non-ID-TLR, n (%) | 0 (0) | 0 (0) | 0 (0) | 1 (0.93)* | 1 (0.93) |
| TVR ² (non-target lesion), n (%) | 0 (0) | 0 (0) | 0 (0) | 3 (2.80) | 3 (2.80) |
| Scaffold thrombosis, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Cumulative MACE ³ , n (%) | 0 (0) | 0 (0) | 1 (0.93) | 2 (1.87) | 2 (1.87) |


*Aminophylline-induced anaphylactic shock. *Revascularisation was carried out due to non-ischæmia-driven in-scaffold restenosis. ¹ Ischæmia-driven target lesion revascularisation. ² Target vessel revascularisation. ³ Major adverse cardiac events

Table 3. Paired quantitative coronary angiography analysis.


| Parameters | Post- procedure (n=29) | 6-month (n=29) | 2-year (n=29) | p-values post-procedure – 6 months | p-values 6 months – 2 years | p-values post-procedure – 2 years | Friedman p-value |
|------------------------------------|---------------------------|-------------------|------------------|--|-----------------------------------|---|---------------------|
| In-segment reference diameter, mm | 3.05±0.45 | 2.99±0.39 | 3.05±0.43 | 0.77 | 0.71 | 0.78 | 0.03 |
| In-scaffold reference diameter, mm | 3.18±0.40 | 3.12±0.37 | 3.14±0.41 | 0.74 | 0.94 | 0.22 | 0.09 |
| In-segment MLD ¹ , mm | 2.69±0.36 | 2.60±0.36 | 2.46±0.41 | 0.47 | 0.31 | 0.00 | 0.00 |
| In-scaffold MLD, mm | 2.84±0.33 | 2.75±0.36 | 2.60±0.37 | 0.55 | 0.34 | 0.00 | 0.00 |
| In-scaffold mean diameter, mm | 3.04±0.32 | 3.05±0.36 | 2.83±0.39 | 0.98 | 0.19 | 0.00 | 0.00 |
| In-segment DS ² , % | 10.99±6.68 | 13.02±8.08 | 19.0±10.9 | 0.21 | 0.03 | 0.00 | 0.00 |
| In-scaffold DS, % | 10.31±6.73 | 11.78±7.48 | 16.6±10.0 | 0.35 | 0.04 | 0.00 | 0.01 |
| In-segment late lumen loss, mm | – | 0.15±0.22 | 0.23±0.32 | – | 0.18 | – | 0.04 |
| In-scaffold late lumen loss, mm | – | 0.13±0.22 | 0.24±0.34 | – | 0.10 | – | 0.01 |

¹ Mean lumen diameter. ² Diameter stenosis

MeRes1 Trial




A.H. 1982 – NSTEMI bočnej steny



OCT pred plánovaním PCI




Predilatácia




Ryurei 3,5/20 mm 12 atm

Implantácia MeRes 100



MeRes100 3,5/24 mm 10 atm

Postdilatacia




Sapphire NC 3,75/18 mm 18 atm



Sapphire NC 3,75/18 mm 18 atm



Výsledný náález



Kontrolné OCT




A.S. 1959 – CHKS CCS III





Predilatácia




Sapphire 3,0/15 mm 14 atm



OCT pred plánovaním implantácie



Implantácia MeRes 100



MeRes100 3,5/24 mm 10 atm




Sapphire NC 3,75/15 mm 16 atm



Sapphire NC 3,75/15 mm 16 atm

Výsledný nále



**Ďakujem
za pozornosť**

2026 © SAIK

